AI assistant
Glenmark Pharmaceuticals ltd — Capital/Financing Update 2018
Oct 9, 2018
62608_rns_2018-10-09_9cfded9d-150d-4e93-8a55-4de546e677fb.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [34 x 32] intentionally omitted <==
==> picture [149 x 44] intentionally omitted <==
October 9, 2018
To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001
To,
The Manager – Listing, National Stock Exchange of India Ltd., Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
Ref: Scrip Code: 532296
Ref: Scrip Name: GLENMARK
Dear Sirs,
Re: Intimation of Settlement by Glenmark Pharmaceuticals Limited (“Company”) of buyback of U.S.$86.5 million (“Buyback FCCBs”) of its U.S.$200 million 2 per cent resettable onward starting equity linked securities due 28 June 2022 (“FCC Bonds”)
This is further to our letters dated 1 October 2018 and 3 October 2018, regarding buyback in respect of the FCC Bonds issued in 2016, which are currently listed on the Singapore Exchange Securities Trading Limited.
The Company wishes to announce that the buyback of the Buyback FCCBs was completed on 5 October 2018 and the registrar and transfer agent has cancelled the Buyback FCCBs. Accordingly, the aggregate principal amount of FCC Bonds that remain outstanding as of the date hereof is U.S.$ 113,500,000.
We request you to take this on record, and to treat the same as compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
Thanking you
Yours faithfully,
For Glenmark Pharmaceuticals Limited
HARISH VINAYAK Digitally signed by HARISH VINAYAK KUBER KUBER Date: 2018.10.09 19:11:08 +05'30' Harish Kuber
Company Secretary Compliance Officer
Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)
Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [email protected]